Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- percentage of cancer patients that accept and attend the early palliative care programme
- Status
- Completed
- Last Updated
- 10 months ago
Overview
Brief Summary
The objective of this phase 2 study is to evaluate the feasibility of an early palliative care intervention for metastatic cancer patients. Feasibility will be assessed in terms of percentage of patients that accept the proposal of the early palliative care intervention and that effectively start to be followed in the palliative care out-patient clinic. The study will be performed in a consecutive series of newly diagnosed patients affected by lung cancer (NSCLC or SCLC, stage IIIb, IV), mesothelioma (stage II, IV), pancreas (stage IV), stomach (stage IIIb-IV).
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients within 8 weeks of cancer diagnosis confirmed by histology or cytology
- •lung cancer (NSCLC or SCLC) stage IIIb-IV OR mesothelioma stage III-IV OR pancreas cancer stage IV, OR gastric cancer stage IIIb-IV
- •age more than 18 years
- •performance status (ECOG) ≤ 2;
- •ability to read, understand and fill-in the questionnaires
- •written informed consent to the study
Exclusion Criteria
- •any chemotherapy, radiotherapy or ormonotherapy for any tumour in the past 12 months
Outcomes
Primary Outcomes
percentage of cancer patients that accept and attend the early palliative care programme
Time Frame: up to 30 days after the diagnosis of cancer
percentage of eligible cancer patients that accept the proposal of the intervention (the early palliative care programme) and that, by 30 days after the diagnosis, effectively start to be followed by the Palliative Care Unit
Secondary Outcomes
- percentage of cancer patients that receive the proposal of early palliative by the oncologists-pneumologists(up to 30 days after the diagnosis of cancer)